Pharmacological modulation of rat monocytes: in vivo effects on Ia expression and interleukin-1 production.
We have shown that during the developing phase of adjuvant disease (AD) in rats the expression of MHC class II (Ia) antigens on blood monocytes (BM) was enhanced. The results of a study in established AD are reported now. Four agents were tested: indomethacin and diclofenac-sodium (1 mg/kg/day); levamisole and prinomide (10 mg/kg/day), administered orally from day 18-31 after induction of AD. We assessed the following BM parameters: Ia expression, interleukin-1 (sIL-1) production, and membrane bound IL-1 (mIL-1). In AD Ia expression was enhanced, no changes occurred in mIL-1 or sIL-1. Indomethacin treatment reduced sIL-1 production, levamisole Ia expression and mIL-1 activity, prinomide all three parameters measured and diclofenac, though clinically effective, none.
Schenkelaars
E J
EJ
CIBA-GEIGY Corporation, Pharmaceuticals Division, Summit, NJ 07901.
Singh
H N
HN
Goldberg
R L
RL
Doughty
J R
JR
Peppard
J
J
DiPasquale
G
G
Quagliata
F
F
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000276:immunology; D015232:Dinoprostone / Q000096:biosynthesis; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000235:genetics; D008297:Male; D009000:Monocytes / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000949:Histocompatibility Antigens Class II; D007375:Interleukin-1; D015232:Dinoprostone